Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market

Apr 27 2023

• By Alaric DeArment

Lilly announced its first quarter 2023 earnings • Source: Shutterstock

Related Content

CAR-Ts May Be Closer Competitors To Lilly’s Jaypirca Than Fellow BTK Inhibitors

Jan 30 2023

Lilly Offloads Baqsimi To Amphastar While Investing In Mounjaro Head-To-Head Trial

Apr 24 2023

Lilly Settles On Rolling Submission For Tirzepatide In Obesity

Oct 07 2022

Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise

May 13 2022

Tirzepatide’s Glowing Obesity Data Steal Show On Lilly’s Earnings Call

Apr 28 2022

Related Companies

Eli Lilly and Company

Novo Nordisk A/S

Gilead Sciences, Inc.

Johnson & Johnson

AbbVie Inc.

Additional Topics

Sales & Earnings Clinical Trials Commercial Metabolic Disorders BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.